Takeda Submits Application For Insomnia Drug Remelteon In Japan
This article was originally published in PharmAsia News
Executive Summary
On Feb. 29, Takeda applied for approval for sleeping pill remelteon (TAK-375) with Japan's Ministry of Health, Labor and Welfare. Remelteon works by selectively targeting two melatonin receptors in the brain, MT1 and MT2. By acting on these receptors, the body's sleep-wake cycle is regulated and physiological sleep is promoted. Because it did not show evidence for potential abuse or dependence in clinical studies, remelteon is the first insomnia medication not regulated by the U.S. Drug Enforcement Administration. Approved by the U.S. FDA in 2005, remelteon is marketed under the brand name Rozerem. Takeda also applied for approval with the European Medicines Agency in March 2007. (Click here for more - Japanese language
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.